Cargando…
STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report
Cancers harboring serine threonine kinase (STK11) alteration or SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1 (SMARCB1) mutation are conventionally considered as treatment-refractory to immune checkpoint inhibitors or chemotherapy, respectively. Ho...
Autores principales: | Chen, Jianxin, Wang, Junhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911826/ https://www.ncbi.nlm.nih.gov/pubmed/36776287 http://dx.doi.org/10.3389/fonc.2023.1088534 |
Ejemplares similares
-
Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
por: Singh, Amisha, et al.
Publicado: (2022) -
SMARCB1/INI1 loss in skull base conventional chordomas: a clinicopathological and molecular analysis
por: Righi, Alberto, et al.
Publicado: (2023) -
Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021) -
The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review
por: Cremen, Sinead, et al.
Publicado: (2022) -
Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)